CalciMedica Past Earnings Performance
Past criteria checks 0/6
CalciMedica's earnings have been declining at an average annual rate of -2.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-2.5%
Earnings growth rate
20.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -150.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How CalciMedica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -14 | 9 | 13 |
| 30 Jun 24 | 0 | -13 | 9 | 13 |
| 31 Mar 24 | 0 | -15 | 9 | 12 |
| 31 Dec 23 | 0 | -34 | 10 | 12 |
| 30 Sep 23 | 0 | -30 | 9 | 11 |
| 30 Jun 23 | 0 | -28 | 9 | 10 |
| 31 Mar 23 | 0 | -25 | 8 | 8 |
| 31 Dec 22 | 0 | -9 | 6 | 8 |
| 30 Sep 22 | 0 | -14 | 6 | 9 |
| 31 Dec 21 | 0 | -24 | 5 | 16 |
Quality Earnings: CALC is currently unprofitable.
Growing Profit Margin: CALC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CALC is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare CALC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CALC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: CALC has a negative Return on Equity (-150.48%), as it is currently unprofitable.